Assays on progressed/priority compounds
The primary goal of the consortium (ENABLE) is to create a drug discovery platform with the expertise and resources to prosecute multiple antibacterial programmes in parallel to boost the overall pipeline in the antibacterial area. The profiling specified in this document is included in a screening funnel describe in the following 2 paragraphs:
Tier 3 H2L. Assays on progressed/priority compounds.
3.21. In vitro pharmacology profiling. Test at 10 µM against a profiling panel of (c. 30) human enzymes/receptors/transporters/ion channels. For key targets with 50 % inhibition at 10 µM, IC50 will be measured.
Tier 7 L2C (Profiling of advanced Lead compounds)
7.7. In vitro pharmacology profiling. Test at 10 µM against a profiling panel (c. 100 human enzymes/receptors/transporters/ion channels). For key targets with 50 % inhibition at 10 µM, IC50 will be measured. For those targets with IC50 below 1 µM, functional effects will be measured.
Sista ansökningsdag
Tidsfristen för mottagande av anbud var 2015-01-22.
Upphandlingen offentliggjordes den 2014-12-03.
Vem?
Vad?
Var?
Upphandlingshistorik
| Datum |
Dokument |
| 2014-12-03
|
Meddelande om upphandling
|